Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
| Catalogue No. | Description | Pack Size | Price | Qty |
|
|---|---|---|---|---|---|
| 10-1986-02 | 5"-Trimethoxystilbene Cap Phosphoramidite | 0.25g | £400.00£376.20Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1986-90 | 5"-Trimethoxystilbene Cap Phosphoramidite | 100µmoles | £156.00£148.20Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
Catalog Number: 10-1986-xx
Description: 5"-Trimethoxystilbene Cap Phosphoramidite
| (3,4,5-trimethoxystilbene-4"-yl)-(3-carboxamidopropyl)-1-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite | ||
| Formula: C30H42N3O6P | M.W.: 571.65 | F.W.: 433.39 |
Diluent: Anhydrous AcetonitrileAdd fresh diluent to product vial to recommended concentration and swirl vial occasionally over several minutes until product is completely dissolved.(Some oils may require between 5 and 10 minutes.) Use care to maintain anhydrous conditions.In case of transfer to alternate vial type, ensure recipient vial has been pre-dried. For more information, see http://www.glenres.com/Technical/TB_ABITransfer.pdf. |
| Coupling: No changes needed from standard method recommended by synthesizer. |
| Deprotection: No changes needed from standard methold recommended by synthesizer. |
| Storage: Freezer storage, -10 to -30°C, dry |
| Stability in Solution: 6 months |
Melting point increases of over 10 °C per modification can be realized forshort duplexes.1,2 The caps fit canonical Watson-Crick base pairs and do notstack well on mismatched base pairs. This leads to increased base pairingselectivity at the terminal and the penultimate position of oligonucleotidesfeaturing the caps. Base pairing fidelity is usually low at the termini, wherefraying occurs frequently in the absence of caps. The beneficial effects of thecaps are also realized when longer target strands are bound, so there is no needfor blunt ends for the duplexes formed.1,2 The caps, when attached to the 5’terminus of an oligonucleotide, also facilitate purification as theirlipophilicity leads to prolonged retention on reversed phase columns orcartridges. Finally, capping of termini may discourage the degradation ofoligonucleotides by exonucleases.
3’-Uaq Cap CPG, a Uridine support modified with a 2’-anthraquinone residue, is the most effective oligonucleotide cap known todate.3,4 For short hybrid duplexes between DNA probes and RNA target strands,the increase in Tm is up to 18 °C and the modification is effective inincreasing the Tm of DNA:DNA, RNA:RNA, and DNA:RNA hybrid duplexes. 3’-Uaq Capalso increases probe specificity by depressing the melting point of terminalmismatches.
Caps for Increased Duplex Stability and Base-Pairing Fidelity at Termini
New cap structures allow for the preparation of hybridization probes with increased affinity for complementary sequences. The monomers used to prepare capped oligonucleotides are phosphoramidites that can be readily introduced via automated DNA synthesis at the end of solid phase syntheses. The caps favor the formation of stable Watson-Crick duplexes by stacking on the terminal base pair.
Melting point increases of over 10 °C per modification can be realized for short duplexes.1,2 The caps fit canonical Watson-Crick base pairs and do not stack well on mismatched base pairs. This leads to increased base pairing selectivity at the terminal and the penultimate position of oligonucleotides featuring the caps. Base pairing fidelity is usually low at the termini, where fraying occurs frequently in the absence of caps. The beneficial effects of the caps are also realized when longer target strands are bound, so there is no need for blunt ends for the duplexes formed.1,2 The caps, when attached to the 5’ terminus of an oligonucleotide, also facilitate purification as their lipophilicity leads to prolonged retention on reversed phase columns or cartridges. Finally, capping of termini may discourage the degradation of oligonucleotides by exonucleases.
3’-Uaq Cap CPG, a Uridine support modified with a 2’- anthraquinone residue, is the most effective oligonucleotide cap known to date.3,4 For short hybrid duplexes between DNA probes and RNA target strands, the increase in Tm is up to 18 °C and the modification is effective in increasing the Tm of DNA:DNA, RNA:RNA, and DNA:RNA hybrid duplexes. 3’-Uaq Cap also increases probe specificity by depressing the melting point of terminal mismatches.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
MSDS
| Glen Report 6.1: NEW LABELLING REAGENTS |
| Glen Report 18.1: Caps for Increased Duplex Stability and Base-Pairing Fidelity at Termini |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
(1) Dogan, Z.; Paulini, R.; Rojas Stütz, J. A.; Narayanan, S.; Richert, C. J. Am. Chem. Soc. 2004, 126, 4762-4763.
(2) Narayanan, S.; Gall, J.; Richert, C. Nucleic Acids Res. 2004, 32, 2901-2911.
(3) A. Patra, C. Richert, J. Amer. Chem. Soc., 2009, 131, 12671-12681.
(4) C. Ahlborn, K. Siegmund, C. Richert, J. Amer. Chem. Soc., 2007, 129, 15218-15232.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
5"-Trimethoxystilbene Cap Phosphoramidite
| (3,4,5-trimethoxystilbene-4"-yl)-(3-carboxamidopropyl)-1-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite | ||
| Formula: C30H42N3O6P | M.W.: 571.65 | F.W.: 433.39 |
Diluent: Anhydrous AcetonitrileAdd fresh diluent to product vial to recommended concentration and swirl vial occasionally over several minutes until product is completely dissolved. (Some oils may require between 5 and 10 minutes.) Use care to maintain anhydrous conditions. In case of transfer to alternate vial type, ensure recipient vial has been pre-dried. For more information, see http://www.glenres.com/Technical/TB_ABITransfer.pdf. |
| Coupling: No changes needed from standard method recommended by synthesizer. |
| Deprotection: No changes needed from standard methold recommended by synthesizer. |
| Storage: Freezer storage, -10 to -30°C, dry |
| Stability in Solution: 6 months |
| Material Safety Data Sheet |
EXTINCTION DATA
| Item | Nucleoside | λMax-1 | Emax-1 | λMax-2 | Emax-2 | E260 |
| (nm) | (ml/µmole) | nm | (ml/µmole) | (ml/µmole) | ||
| 10-1986 | 338 | 36.0 | 36.0 | 10.6 |
Literature Highlights
| Glen Report 6.1: NEW LABELLING REAGENTS |
| Glen Report 18.1: Caps for Increased Duplex Stability and Base-Pairing Fidelity at Termini |
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 4.37 | 132.33 | 79.4 | 49.63 | 36.09 | 26.47 | 6.62 |
| 10-1986-90 | 100µmoles | .057grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 6.53 | .067 | 124.2 | 77.63 | 56.45 | 7.76 | |
| 10-1986-90 | 100µmoles | .057grams | 1.5 | .067 | 23.6 | 14.75 | 10.73 | 1.48 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 6.53 | .067 | 125.8 | 78.63 | 57.18 | ||
| 10-1986-90 | 100µmoles | .057grams | 1.5 | .067 | 25.2 | 15.75 | 11.45 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-Trimethoxystilbene Cap Phosphoramidite
5"-Trimethoxystilbene Cap Phosphoramidite
Glen Research
EXTINCTION DATA
| Item | Nucleoside | λMax-1 | Emax-1 | λMax-2 | Emax-2 | E260 |
| (nm) | (ml/µmole) | nm | (ml/µmole) | (ml/µmole) | ||
| 10-1986 | 338 | 36.0 | 36.0 | 10.6 |
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 4.37 | 132.33 | 79.4 | 49.63 | 36.09 | 26.47 | 6.62 |
| 10-1986-90 | 100µmoles | .057grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 6.53 | .07 | 124.2 | 77.63 | 56.45 | 7.76 | |
| 10-1986-90 | 100µmoles | .057grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1986-02 | 0.25grams | .25grams | 6.53 | .07 | 125.8 | 78.63 | 57.18 | ||
| 10-1986-90 | 100µmoles | .057grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
AthensResearch&Technology公司位于美国乔治亚州雅典市，从1986年以来一直致力于纯化高纯度，高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白，血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来，世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。我们提供优质，可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务，AthensResearch&Technology公司能够根据您的项目要求提供无与伦比的试剂。
公司主要产品：一、凝血因子相关系列产品：包括多款从人血浆、血小板中分离纯化的凝血因子相关蛋白。二、酶及抑制剂系列产品：包括多款从人血浆、红细胞分离纯化的a-抗糜蛋白酶、a1/2抗胰蛋白酶、抗凝血酶、C1酯酶抑制因子、Calpain-1等酶及其抑制剂产品。三、免疫球蛋白系列产品：包括多款从人血浆、骨髓瘤、初乳以及狗和小鼠血浆中分离纯化的免疫球蛋白产品。四、脂蛋白及载脂蛋白系列产品：包括包括多款从人血浆中分离纯化的载脂蛋白及脂蛋白（高密度、中等密度、低密度、极低密度脂蛋白）产品。五、低内毒素蛋白系列产品：包括多款适宜于细胞培养的低内毒素脂蛋白、免疫球蛋白及转铁蛋白产品。六、乳蛋白系列产品：包括从人乳中分离纯化的乳白蛋白、乳铁传递蛋白及分泌型免疫球蛋白A。七、中性粒细胞源蛋白系列产品：包括多款纯化分离自人中性粒细胞的Azurocidin 、CathepsinG及Lactoferrin等蛋白产品。八、血小板相关系列产品：包括纯化分离自人血小板的血小板因子4及凝血酶致敏蛋白。九、转铁蛋白及脱铁转铁蛋白（APOTRANSFERRINS）系列产品：包括多款纯化分离自人、大小鼠、狗及食蟹猴血浆中的转铁蛋白/脱铁转铁蛋白，可应用于细胞或组织培养。十、抗体系列产品：包括多款兔、大鼠、羊源的多克隆抗体产品。
ebiomall.com
